Read by QxMD icon Read


shared collection
112 papers 25 to 100 followers
Albrecht Werner Popp, Nadshathra Varathan, Helene Buffat, Christoph Senn, Romain Perrelet, Kurt Lippuner
The aim of the present study was to document the changes in bone mineral density (BMD) 1 year after denosumab loss-of-effect following long-term treatment with subcutaneous denosumab 60 mg Q6M during 7 or 10 years and in the absence of any treatment with a bone active substance. All postmenopausal women with osteoporosis who participated to the randomized placebo-controlled FREEDOM core trial and its open-label extension at the University Hospital of Bern, Switzerland, and who accepted to undergo off-treatment follow-up during 1 year after discontinuation, were included (N = 12)...
January 29, 2018: Calcified Tissue International
Jesus Lavado-García, Raul Roncero-Martin, Jose M Moran, Maria Pedrera-Canal, Ignacio Aliaga, Olga Leal-Hernandez, Sergio Rico-Martin, Maria L Canal-Macias
The regular consumption of long-chain omega-3 polyunsaturated fatty acids (LCO3-PUFAs) results in general health benefits. The intake of LCO3-PUFAs has been reported to contribute to bone metabolism. We aimed to investigate the relationships between dietary intakes of LCO3-PUFAs and bone mineral density (BMD) in Spanish women aged 20-79 years old. A total of 1865 female subjects (20-79 years old) were enrolled, and lumbar (L2, L3, L3 and total spine), hip (femoral neck (FN), femoral trochanter (FT) and Ward's triangle (WT)) bone mineral density (BMD) were measured by dual energy X-ray absorptiometry (DXA)...
2018: PloS One
Teruki Sone, Naohiro Kon, Kenneth W Gaither, Naoki Okubo, Taisuke Osakabe, Yutaka Nakayama, Masao Fukunaga, Masako Ito, Toshitaka Nakamura
Denosumab, a human monoclonal antibody against RANK ligand, is shown to have strong anti-fracture effects in Japanese osteoporosis patients. However, there have been no data showing actions on Japanese bone architecture. Here we show that denosumab continuously improves several geometrical parameters calculated by hip structural analysis for 3 years. Compared to placebo, denosumab significantly increased bone mineral density, cortical thickness and cross sectional area in all of the three analyzed areas: the narrow neck, intertrochanter and femoral shaft...
December 2017: Bone Reports
Stergios A Polyzos, Athanasios D Anastasilakis, Zoe A Efstathiadou, Polyzois Makras, Nikolaos Perakakis, Jannis Kountouras, Christos S Mantzoros
INTRODUCTION: Irisin is a myokine/adipokine induced by the exercise in mice and humans, which is proposed to induce "browning" of white adipose tissue, its primary target, thus increasing thermogenesis and energy expenditure. Since its identification, irisin has been linked to favorable effects on metabolic diseases, including obesity, type 2 diabetes mellitus (T2DM), lipid metabolism and cardiovascular disease (CVD), nonalcoholic fatty liver disease (NAFLD), polycystic ovary syndrome (PCOS), and metabolic bone diseases...
February 2018: Endocrine
Ian Varley, David C Hughes, Julie P Greeves, Trent Stellingwerff, Craig Ranson, William D Fraser, Craig Sale
OBJECTIVES: To determine, in conjunction with a wider investigation, whether 11 genetic variants in the vicinity of vitamin D, collagen and Wnt signalling pathways were associated with stress fracture injury in the Stress Fracture Elite Athlete (SFEA) cohort. DESIGN: Genotype-phenotype association study. METHODS: Self-reported stress fracture history and demographic data were recorded in 518 elite athletes, 449 male and 69 female (mean age 24...
November 7, 2017: Journal of Science and Medicine in Sport
Zhicai Zhang, Feifei Pu, Zengwu Shao
Objective: The meta-analysis was used to evaluate the skeletal-related events (SREs) and efficacy of denosumab versus zoledronic acid (ZA) in patients with bone metastases. Methods: The data of this meta-analysis study were searched from PUBMED, EMBASE, Cochrane Library, Web of Science with Conference Proceedings, Elsevier and China National Knowledge Infrastructure (CNKI) databases till August 2017. Two independent reviewers reviewed the reference lists of relevant articles...
November 2017: Journal of Bone Oncology
Shuan Rao, Verena Sigl, Reiner Alois Wimmer, Maria Novatchkova, Alexander Jais, Gabriel Wagner, Stephan Handschuh, Iris Uribesalgo, Astrid Hagelkruys, Ivona Kozieradzki, Luigi Tortola, Roberto Nitsch, Shane J Cronin, Michael Orthofer, Daniel Branstetter, Jude Canon, John Rossi, Manolo D'Arcangelo, Johan Botling, Patrick Micke, Linnea La Fleur, Karolina Edlund, Michael Bergqvist, Simon Ekman, Thomas Lendl, Helmut Popper, Hiroshi Takayanagi, Lukas Kenner, Fred R Hirsch, William Dougall, Josef M Penninger
Lung cancer is the leading cause of cancer deaths. Besides smoking, epidemiological studies have linked female sex hormones to lung cancer in women; however, the underlying mechanisms remain unclear. Here we report that the receptor activator of nuclear factor-kB (RANK), the key regulator of osteoclastogenesis, is frequently expressed in primary lung tumors, an active RANK pathway correlates with decreased survival, and pharmacologic RANK inhibition reduces tumor growth in patient-derived lung cancer xenografts...
October 15, 2017: Genes & Development
Ernesto Canalis
Skeletal anabolic agents enhance bone formation, which is determined by the number and function of osteoblasts. Signals that influence the differentiation and function of cells of the osteoblast lineage play a role in the mechanism of action of anabolic agents in the skeleton. Wnts induce the differentiation of mesenchymal stem cells toward osteoblasts, and insulin-like growth factor I (IGF-I) enhances the function of mature osteoblasts. The activity of Wnt and IGF-I is controlled by proteins that bind to the growth factor or to its receptors...
February 2018: European Journal of Endocrinology
M Neale Weitzmann
Osteoporosis increases fracture risk, a cause of crippling morbidity and mortality. The immunoskeletal interface (ISI) is a centralization of cell and cytokine effectors shared between skeletal and immune systems. Consequently, the immune system mediates powerful effects on bone turnover. Physiologically, B cells secrete osteoprotegerin (OPG), a potent anti-osteoclastogenic factor that preserves bone mass. However, activated T cells and B cells secrete pro-osteoclastogenic factors including receptor activator of Nuclear factor-kappaB (NF-kB) ligand (RANKL), Interleukin (IL)-17A, and tumor necrosis factor (TNF)-α promoting bone loss in inflammatory states such as rheumatoid arthritis...
October 2017: Toxicologic Pathology
Sebastian Butscheidt, Tim Rolvien, Uwe Kornak, Felix N Schmidt, Thorsten Schinke, Michael Amling, Ralf Oheim
The main hallmark of high bone mass (HBM) disorders is increased bone mineral density, potentially visible in conventional radiographs and quantifiable by other radiographic methods. While one of the most common forms of HBM is CLCN7-related autosomal dominant osteopetrosis type II (ADO II), there is no consensus on diagnostic thresholds. We therefore wanted to assess whether CLCN7-osteopetrosis patients differ from benign HBM cases in terms of (1) bone mineral density, (2) bone structure, and (3) microarchitectural abnormalities...
October 10, 2017: Calcified Tissue International
Hiroya Takami, Kazunori Washio, Hiromichi Gotoh
Denosumab increases bone mineral density (BMD) in patients not receiving hemodialysis therapy. However, limited data are available in the literature concerning the use of denosumab in hemodialysis patients. We treated male hemodialysis patients with low radius BMD with denosumab therapy for 1 year and evaluated its effect on radius BMD. Seventeen patients were treated with denosumab 60 mg every 6 months, and 20 patients were not treated with denosumab (control group). At seven days, the mean corrected calcium level decreased from 9...
2017: International Journal of Nephrology
Clifford J Rosen
New England Journal of Medicine, Volume 377, Issue 15, Page 1479-1480, October 2017.
October 12, 2017: New England Journal of Medicine
(no author information available yet)
No abstract text is available yet for this article.
August 1, 2017: Rheumatology
Helen Senderovich, Henry Tang, Samuel Belmont
INTRODUCTION: The primary non-pharmacological management recommended for patients with osteoporosis (OP) is exercise, but whether it should be high-force, resistive, or other means can be obscure. OBJECTIVE: To describe the role of exercises in osteoporotic fracture prevention, identify effects and potential risks of high-force exercises, detect the optimal exercises to combat OP, and explore the challenges that might arise from interventions. METHODS: A search on MEDLINE and Cochrane databases was conducted on the role of exercises in preventing osteoporotic fractures from 1989 onwards, leading to 40 results, including op-ed pieces, qualitative studies, randomized clinical trials (RCTs) (n=5), and RCT follow-up studies (n=1)...
July 1, 2017: Rambam Maimonides Medical Journal
Chuandong Wang, Fei Xiao, Xinhua Qu, Zanjing Zhai, Guoli Hu, Xiaodong Chen, Xiaoling Zhang
Postmenopausal osteoporosis is a disease characterized by excessive osteoclastic bone resorption. Some anti-diabetic drugs were demonstrated for anti-osteoclastic bone-loss effects. The present study investigated the skeletal effects of chronic administration of sitagliptin, a dipeptidyl peptidase IV (DPP IV) inhibitor that is increasingly used for type 2 diabetes treatments, in an estrogen deficiency-induced osteoporosis and elucidated the associated mechanisms. This study indicated that sitagliptin effectively prevented ovariectomy-induced bone loss and reduced osteoclast numbers in vivo...
2017: Frontiers in Pharmacology
Gonçalo Boleto, Moustapha Dramé, Isabelle Lambrecht, Jean-Paul Eschard, Jean-Hugues Salmon
The aim of this study was to evaluate the structural effect of denosumab on patients with rheumatoid arthritis (RA). We performed a systematic review of the literature in the following databases: PubMed, Cochrane, Web of Science, , and the WHO International Clinical Trials Registry Platform. All studies evaluating the structural effect of denosumab on RA and meeting predefined criteria were included. Data regarding disease activity, progression of joint damage, joint space narrowing, and safety were recorded...
August 2017: Clinical Rheumatology
T Kuroda, H Ohta, Y Onoe, N Tsugawa, M Shiraki
This study investigated the relationships between intakes of polyunsaturated fatty acids, omega-3 fatty acids, and omega-6 fatty acids and bone mineral density in Japanese women aged 19 to 25 years. Intakes of omega-3 fatty acids (n-3) were positively associated with peak bone mass at the hip. INTRODUCTION: Lifestyle factors such as physical activity and nutrition intake are known to optimize the peak bone mass (PBM). Recently, intake of polyunsaturated fatty acids (PUFAs) has been reported to contribute to bone metabolism...
June 23, 2017: Osteoporosis International
Sarah M Bristow, Gregory D Gamble, Anne M Horne, Ian R Reid
A high Ca intake has been recommended for osteoporosis prevention; however, little research has examined the relationship between dietary Ca and bone health in men. We examined associations between dietary Ca intake, bone mineral density (BMD) and change in BMD at the total body, hip and spine over 2 years in a cohort of men (mean age 57 years, BMI 26 kg/m2) from a trial. Data from the total cohort (n 323) were used in the analysis of Ca intake and BMD at baseline, and data from the placebo group (n 99) were used in the longitudinal analysis of Ca intake and change in BMD...
May 2017: British Journal of Nutrition
Joy N Tsai, Kyle K Nishiyama, David Lin, Amy Yuan, Hang Lee, Mary L Bouxsein, Benjamin Z Leder
In postmenopausal osteoporosis, switching from teriparatide to denosumab results in continued bone mineral density (BMD) gains whereas switching from denosumab to teriparatide results in BMD loss. To assess the effects of these transitions on bone microarchitecture and strength, we performed high-resolution peripheral QCT (HR-pQCT) at the distal tibia and radius in postmenopausal osteoporotic women who received 24 months of teriparatide 20 μg daily followed by 24 months of denosumab 60 mg every 6 months, 24 months of denosumab followed by 24 months of teriparatide, or 24 months of both medications followed by 24 months of denosumab...
October 2017: Journal of Bone and Mineral Research: the Official Journal of the American Society for Bone and Mineral Research
Sylvie F Hall, Stephanie W Edmonds, Yiyue Lou, Peter Cram, Douglas W Roblin, Kenneth G Saag, Nicole C Wright, Michael P Jones, Fredric D Wolinsky
OBJECTIVES: As many as one-half of patients recommended for osteoporosis pharmacotherapy do not take their medications. To identify intervention targets, we examined patient characteristics associated with nonadherence to recommended pharmacotherapy and their reasons for nonadherence. METHODS: Data come from the Patient Activation after DXA Result Notification (PAADRN) study, a randomized controlled trial of 7749 patients aged 50 years or older presenting for dual-energy X-ray absorptiometry (DXA) at 3 health centers in the United States...
July 2017: Journal of the American Pharmacists Association: JAPhA
2017-06-14 18:01:51
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"